Connect your AI

BridgeBio Pharma BBIO Accrued compensation and employee benefits

Accrued compensation and employee benefits at other companies

Encompass Health CorporationEHC

$9.5M-58.7%

Credo Technology Group Holding LtdCRDO

$12.58M+128%

Donaldson CompanyDCI

-$3.25M-141%

Arthur J. GallagherAJG

-$411M+1.2%

Huntington Ingalls IndustriesHII

$219M+7.4%

Credo Technology Group Holding LtdCRDO

$2.91M+64.1%

Other financials

Income statement

Revenue$194.5M+66.8%

Gross profit$184.6M+61.9%

Operating income-$106.0M-1.5%

Net income-$166.6M+1.8%

EPS (diluted)-$0.84+4.5%

Balance sheet

Cash & equivalents$882.0M+62.5%

Total debt$3.3B+32,101%

Total equity-$2.3B-38.2%

Total assets$1.4B+55.5%

Cash flow

Operating cash flow-$197.3M+1.0%

CapEx$69.0K—

Free cash flow-$197.3M+0.9%

Valuation

Market cap$12.98B+119%

Enterprise value$15.36B+178%

P/S22.4×-24.1×

Profitability

Gross margin95.1%-0.2pp

Operating margin-90.5%-41.2pp

Net margin-125.9%-54.5pp

FCF margin-76.8%—

Returns & leverage

Return on equity-216.8%—

Debt / equity2×—

Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities.

The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BridgeBio Pharma's accrued compensation and employee benefits.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is BridgeBio Pharma's accrued compensation and employee benefits?: BridgeBio Pharma (BBIO) reported accrued compensation and employee benefits of -$37.48M in Q1 2026.
How has BridgeBio Pharma's accrued compensation and employee benefits changed year-over-year?: BridgeBio Pharma's accrued compensation and employee benefits decreased by 93.5% year-over-year, from -$19.36M to -$37.48M.